Physician profile
John J Nolan
NPI 1659373835
$13,763.74
in general payments reported to CMS, 2019-2025
50 companies · $1,621 in 2025
The $1,621 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,019 · 2020: $1,584 · 2021: $1,704 · 2022: $2,085 · 2023: $2,827 · 2024: $1,924 · 2025: $1,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,301 · Education: $70.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,301.25 |
| Education | $70.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,298.60 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,813.09 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,036.79 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $997.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $878.98 | 2019-2025 | Mounjaro, Jardiance |
| Abbott Laboratories | $848.43 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $833.51 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $576.18 | 2019-2022 | |
| Glaxosmithkline, LLC. | $491.20 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $366.11 | 2019-2024 | Belsomra, Gardasil 9, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $250.61 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $236.40 | 2019-2025 | Repatha, Otezla |
| Exact Sciences Corporation | $216.86 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $209.29 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $207.26 | 2019-2025 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Nolan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.